Expression levels of miR-21, miR-146b and miR-326 as potential biomarkers in Behcet's disease

2019 ◽  
Vol 13 (16) ◽  
pp. 1339-1348
Author(s):  
Golamreza Jadideslam ◽  
Khalil Ansarin ◽  
Ebrahim Sakhinia ◽  
Zohreh Babaloo ◽  
Alireza Abhari ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Study Groups ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Behcet's Disease ◽  
Expression Rate ◽  
Eye Involvement

Aim: Behcet's disease (BD) is a vasculitis. Lines of evidence suggest miRNAs as diagnostic and prognostic markers in autoimmune diseases. This study was designed to investigate the potential role of miR-21, miR-146b and miR-326 as biomarkers for diagnosis, predicting organs involvement and measuring BD activity. Patients & methods: In this cross-sectional study, the study groups consisted of 46 BD patients and 70 age- and sex-matched healthy volunteers. The expression rates of three miRNAs were determined by quantitative real-time PCR. Results: Our results demonstrated significantly lower expression of miR-21 and miR-146b and higher expression of miR-326 in BD patients. MiR-21 expression rate in patients with severe eye involvement and miR-326 expression rate in patients with uveitis and severe eye involvement were increased. Conclusion: MiR-326 expression rate can be used as a biomarker for prediction of uveitis and severe eye involvement in patients with BD.

scholarly journals Epidemiology and treatment of Behçet’s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Nevin Hammam ◽  
Jing Li ◽  
Michael Evans ◽  
Julia L. Kay ◽  
Zara Izadi ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Systemic Vasculitis ◽  
Patient Characteristics ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Behcet's Disease ◽  
Endemic Areas ◽  
The U.S

Abstract Background Behçet’s disease (BD), a chronic systemic vasculitis, has distinct geographical and ethnic variation. Data regarding the epidemiology of patients with BD in the U.S. are limited; therefore, we sought to describe BD patient characteristics and medication use in the U.S., and compared them with data from patients from endemic regions. Methods We conducted a cross-sectional study using data from the RISE registry (2014–2018). Patients aged ≥ 18 years with BD were included. Sociodemographic and treatment information was extracted. We compared patients from the RISE registry to data from other published studies of patients with BD from endemic areas. Results One thousand three hundred twenty-three subjects with BD from the RISE registry were included. Mean age was 48.7 ± 16.3 years, female to male ratio was 3.8:1, and 66.7% were White. The most frequently used medications included glucocorticoids (67.6%) and colchicine (55.0%). Infliximab and adalimumab were the most used biologics (14.5% and 14.1%, respectively); 3.2% of patients used apremilast. The RISE registry had more women (79.3%), and patients were older compared to previously published BD studies from endemic areas. Methotrexate and TNFi were more commonly reported in RISE (21.8% and 29.4%) compared to studies from Egypt and Turkey. Colchicine, cyclosporine, and cyclophosphamide were more commonly used in cohorts from Egypt, Turkey, and Iran. Conclusions Findings from the largest BD dataset in the U.S. suggest that BD patients are predominantly female. Further research is needed to explore the reasons for the higher prevalence of BD among women in the U.S. and its possible impact on disease severity and management.

Role of miR-146a rs2910164 and UTS2 rs228648 Genetic Variants in Behçet’s Disease

2021 ◽  
pp. 1-10
Author(s):  
Asmaa Kamal ◽  
Fatema T Elgengehy ◽  
Zahraa Elawady ◽  
Nahla A. Fawzy ◽  
Ola El Sisi
Keyword(s):  
Behçet’S Disease ◽  
Genetic Variants ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Behcet's Disease

scholarly journals French recommendations for the management of Behçet’s disease

2021 ◽  
Vol 16 (S1) ◽  
Author(s):  
Isabelle Kone-Paut ◽  
◽  
Stéphane Barete ◽  
Bahram Bodaghi ◽  
Kumaran Deiva ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Initial Assessment ◽  
Diagnostic Process ◽  
Behcet's Disease ◽  
Therapeutic Modalities ◽  
Clinical Presentations ◽  
Key Points

AbstractBehçet’s disease (BD) is a systemic variable vessel vasculitis that involves the skin, mucosa, joints, eyes, arteries, veins, nervous system and gastrointestinal system, presenting with remissions and exacerbations. It is a multifactorial disease, and several triggering factors including oral cavity infections and viruses may induce inflammatory attacks in genetically susceptible individuals. BD vasculitis involves different vessel types and sizes of the vascular tree with mixed-cellular perivascular infiltrates and is often complicated by recurrent thrombosis, particularly in the venous compartment. Several new therapeutic modalities with different mechanisms of action have been studied in patients with BD. A substantial amount of new data have been published on the management of BD, especially with biologics, over the last years. These important therapeutic advances in BD have led us to propose French recommendations for the management of Behçet’s disease [Protocole National de Diagnostic et de Soins de la maladie de Behçet (PNDS)]. These recommendations are divided into two parts: (1) the diagnostic process and initial assessment; (2) the therapeutic management. Thirty key points summarize the essence of the recommendations. We highlighted the main differential diagnosis of BD according to the type of clinical involvement; the role of genetics is also discussed, and we indicate the clinical presentations that must lead to the search for a genetic cause.

scholarly journals The Role of Th17 Cells in the Pathogenesis of Behcet’s Disease

2017 ◽  
Vol 6 (7) ◽  
pp. 74 ◽  
Author(s):  
Yuki Nanke ◽  
Toru Yago ◽  
Shigeru Kotake
Keyword(s):  
Behçet’S Disease ◽  
Th17 Cells ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Behcet's Disease

Role of γδ T cells in Behcet's disease

The Lancet ◽  
1996 ◽  
Vol 347 (9015) ◽  
pp. 1631-1632 ◽  
Author(s):  
J.S.H. Gaston ◽  
Adam Hasan ◽  
Farida Fortune ◽  
Amanda Wilson ◽  
Thomas Lehner
Keyword(s):  
T Cells ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Γδ T Cells ◽  
Behcet's Disease
Sign in / Sign up

Export Citation Format

Share Document